Stanford

Farshad Moradi

Clinical Associate Professor, Radiology - Rad/Nuclear Medicine

CLINICAL OFFICE (PRIMARY)

- **Division of Nuclear Medicine**
  300 Pasteur Dr H-2226
  MC 5281
  Stanford, CA 94305
  Tel (650) 725-4711 **Fax** (650) 498-5047

Bio

CLINICAL FOCUS

- Diagnostic Radiology
- Positron-Emission Tomography
- Nuclear Radiology

ACADEMIC APPOINTMENTS

- Clinical Associate Professor, Radiology - Rad/Nuclear Medicine

ADMINISTRATIVE APPOINTMENTS

- Modality Director, Nuclear Medicine, (2020- present)

PROFESSIONAL EDUCATION

- Residency: UCSD Dept of Radiology (2014) CA
- Board Certification: Diagnostic Radiology, American Board of Radiology (2015)
- Fellowship: Stanford University Radiology Fellowships (2015) CA
- Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2015)
- Internship: University of Massachusetts Internal Medicine Residency (2009) MA
- PhD, California Institute of Technology , Computation and Neural Systems (2007)
- Medical Education: Tehran University of Medical Sciences (2000) Iran

Research & Scholarship

CLINICAL TRIALS

- 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer, Recruiting
- ALS PET-MRI, Recruiting

- Phase III to Test DxPerformance of Copper Cu64 PSMA I&T PET/CT in Intermediate/High/VeryHigh-Risk PC, Recruiting
- Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers, Not Recruiting
- Phase III Test DiagnosticPerformance of Copper Cu 64 PSMA I&T PET/CT in Biochemical Recurrence of PC, Not Recruiting
- FAPI-74, Not Specified
- Phase I Rhenium-186 NanoLiposome (186RNL) via Intraventricular Catheter in Leptomeningeal Metastases, Not Specified
- Phase II 89Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in HNSCC, Not Specified
- Pilot of a 1-Millimeter Resolution Clinical PET System in Head and Neck Cancer Imaging, Not Specified

Publications

PUBLICATIONS

- **ASNR Consensus Statement: Integrating Neuro-PET Interpretation into Neuroradiology Training and Practice.** *AJNR. American journal of neuroradiology*
  Ivanidze, J., Franceschi, A. M., Wintermark, M., Jordan, J. E., Aboian, M., Anderson, J. C., Assadsangabi, R., Benayoun, M. D., Benzinger, T. L., Buchpiguel, C. A., Chiang, G. C., Ebani, E. J., Famuyide, et al
  2025
- **Enhanced 15O-Water PET CBF Quantification Through MR-Guided Reconstruction**
  Khalighi, M., Jiang, B., Moradi, F., Zaharchuk, G.
  SOC NUCLEAR MEDICINE INC.2025
- **Evaluation of Patients with Suspected Parathyroid Adenoma and Negative or Equivocal Tc99m-Sestamibi SPECT/CT Using F18-Fluorocholine PET/CT: Preliminary Results**
  Guja, K., Patel, H., Kebebew, E., Cisco, R., Lin, D., Grady, E., Shah, J., Moradi, F., Song, H., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2025
- **Amyloid PET Radiomics: Correlations with Clinical Features and Neurodegenerative Disease Types**
  Otani, T., Vossler, H., Guja, K., Song, H., Mormino, E., Moradi, F., Davidzon, G.
  SOC NUCLEAR MEDICINE INC.2025
- **Preliminary evaluation of PSMA PET/CT for treatment response assessment of metastatic prostate cancer patients treated with systemic therapies**
  Song, H., Davidzon, G., Moradi, F., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2025
- **[18F]Flurimedrimer, a Novel Nanomedicine Radiotracer, Selectively Targeting Activated Microglia in Human Brain**
  Moradi, F., Dunn, J., James, M., Malik, N., Park, J., Korn, R., El-Shaafey, N., Lomen-Hoerth, C., Shah, V., Cleland, J.
  SOC NUCLEAR MEDICINE INC.2025
- **The Challenge of External Generalisability: Insights from the Bicentric Validation of a [68Ga]Ga-PSMA-11 PET Based Radiomics Signature for Primary Prostate Cancer Characterisation Using Histopathology as Reference.** *Cancers*
  Ghezzo, S., Bharathi, P. G., Duan, H., Mapelli, P., Sorgo, P., Davidzon, G. A., Bezzi, C., Chung, B. I., Samanes Gajate, A. M., Thong, A. E., Russo, T., Brembilla, G., Loening, et al
  2024; 16 (23)
- **Applying Staging PSMA PET/CT in De Novo Metastatic Hormonal Sensitive Prostate Cancer (mHSPC): A Preliminary Single-Center Retrospective Review of Clinical Outcomes**
  Song, H., Xing, J., Duan, H., Davidzon, G., Franc, B., Moradi, F., Srinivas, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2024
- **Automated assessment of oncological FDG PET/CT or PET/MR image quality with deep learning**
  Moradi, F., Bharathi, P., Khalighi, M., Su, K., Spangler-Bickell, M., Jansen, F.
  SOC NUCLEAR MEDICINE INC.2024
- **Can PET image quality be monitored in real time? Prediction of oncological FDG PET image quality using Fast List-Mode Reconstruction of short PET Frames and Deep Learning**
  Moradi, F., Bharathi, P., Khalighi, M., Spangler-Bickell, M., Su, K., Jansen, F., Davidzon, G., Franc, B., Iagaru, A.

SOC NUCLEAR MEDICINE INC.2024

- **Artificial Intelligence-Driven Model for Prostate Cancer Staging with PSMA PET: A Study Integrating Radiomics Features and SVM Classifier**

  Bharathi, P., Ghezzo, S., Duan, H., Mapelli, P., Davidzon, G., Bezzi, C., Chung, B., Gajate, A., Thong, A., Russo, T., Brembilla, G., Loening, A., Ghanouni, et al

  SOC NUCLEAR MEDICINE INC.2024

- **Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*

  Duan, H., Song, H., Davidzon, G. A., Moradi, F., Liang, T., Loening, A., Vasanawala, S., Iagaru, A.

  2024

- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.** *European journal of nuclear medicine and molecular imaging*

  Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al

  2024

- **68Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.** *The Lancet. Oncology*

  Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., Vasanawala, S., Srinivas, S., Brooks, J. D., Hancock, S., Iagaru, A.

  2024

- **Total and anatomically contextualized quantitative ¹⁸F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression-free survival in patients with prostate cancer.**

  Song, H., Anand, A., Sjostrand, K., Ferri, V., Duan, H., Shah, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, et al

  LIPPINCOTT WILLIAMS & WILKINS.2024: 33

- **Assessing the clinical utility of rapid post-therapy whole-body digital SPECT/CT in evaluating early treatment response of ¹⁷⁷Lu-PSMA-617 treatment.**

  Leonio, M., Ferri, V., Duan, H., Shah, J., Moradi, F., Mari Aparici, C., Franc, B., Davidzon, G., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, A., Srinivas, et al

  LIPPINCOTT WILLIAMS & WILKINS.2024: 32

- **PET Imaging of Neuroinflammation in ALS Patients Using ¹⁸F-OP-801, a Novel Nanoimaging Agent**

  Maricich, S. M., Korn, R., Lomen-Hoerth, C., So, Y., Oguno, B., Cleland, J. L., Shah, V., Moradi, F.

  WILEY.2023: S246

- **Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.** *European journal of nuclear medicine and molecular imaging*

  Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., Iagaru, A.

  2023

- **Clinical Radiosynthesis and Translation of [18F]OP-801: A Novel Radiotracer for Imaging Reactive Microglia and Macrophages.** *ACS chemical neuroscience*

  Jackson, I. M., Carlson, M. L., Beinat, C., Malik, N., Kalita, M., Reyes, S., Azevedo, E. C., Nagy, S. C., Alam, I. S., Sharma, R., La Rosa, S. A., Moradi, F., Cleland, et al

  2023

- **Predicting FDG-PET Images From Multi-Contrast MRI Using Deep Learning in Patients With Brain Neoplasms.** *Journal of magnetic resonance imaging : JMRI*

  Ouyang, J., Chen, K. T., Duarte Armindo, R., Davidzon, G. A., Hawk, K. E., Moradi, F., Rosenberg, J., Lan, E., Zhang, H., Zaharchuk, G.

  2023

- **Rapid dynamic reconstruction using list mode data for monitoring PET image quality accurately predicts final image noise and perceived quality**

  Moradi, F., Khalighi, M., Su, K., Zhang, X., Wollenweber, S., Spangler-Bickell, M., Bharathi, P., Franc, B., Davidzon, G., Iagaru, A.

  SOC NUCLEAR MEDICINE INC.2023

- **A Case-Based Primer on FDG PET/CT for Imaging Cardiovascular Infections: Protocol, Interpretation, and Pitfalls.**

Zhou, W., Moradi, F., Davidzon, G., Song, H., Grady, E., Nguyen, J., Franc, B., Aparici, C., Iagaru, A., Shah, J.
SOC NUCLEAR MEDICINE INC.2023

- **Total and Anatomically Contextualized Quantitative 18F-DCFPyL PET at biochemical recurrence predicts subsequent biochemical progression free survival in prostate cancer patients**
  Song, H., Duan, H., Ferri, V., Na, S., Davidzon, G., Franc, B., Aparici, C., Moradi, F., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2023
- **Final Analysis of a Prospective, Single-center, Phase II/III Imaging Trial of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer**
  Duan, H., Moradi, F., Davidzon, G., Liang, T., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2023
- **Modified PROMISE Criteria for Standardized Interpretation of Gastrin Releasing Peptide Receptor (GRPR)-targeted PET**
  Duan, H., Davidzon, G., Moradi, F., Liang, T., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2023
- **Total and anatomically contextualized quantitative 18F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer**
  Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C., Davidzon, G., Franc, B., Moradi, F., Anand, A., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2023
- **SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.** *European journal of nuclear medicine and molecular imaging*
  Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Nguyen, J., Shah, J., Iagaru, A.
  2023
- **Retroperitoneal Inflammation Detected on FDG PET/CT in Patient on Long-Term Immunotherapy.** *Clinical nuclear medicine*
  Khessib, T., Franc, B., Yang, E., Moradi, F.
  2023
- **A Pilot Study of 68Ga-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Kunder, C., Mari Aparici, C., Davidzon, G. A., Moradi, F., Sonn, G. A., Iagaru, A.
  2022
- **A Pilot Study of Ga-68-PSMA11 and 68Ga-RM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
  Duan, H., Ghanouni, P., Daniel, B., Rosenberg, J., Thong, A., Sonn, G. A., Kunder, C., Davidzon, G. A., Aparici, C., Moradi, F., Iagaru, A.
  SPRINGER.2022: S484
- **Posttreatment FDG-PET/CT Hopkins criteria predict locoregional recurrence after definitive radiotherapy for oropharyngeal squamous cell carcinoma.** *Head & neck*
  Miller, J. A., Moradi, F., Sundaram, V., Liang, R., Zhang, C., Nguyen, N. K., Akhtar, F., Liu, Y., Ren, Y., Harandi, N., Weng, Y., Pollom, E. L., Colevas, et al
  2022
- **Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer**
  Duan, H., Song, H., Davidzon, G., Moradi, F., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2022
- **Correlation of 68Ga-RM2 PET with Post-Surgery Histopathology Findings in Patients with Newly Diagnosed Intermediate- or High-Risk Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Duan, H., Baratto, L., Fan, R. E., Soerensen, S. J., Liang, T., Chung, B. I., Thong, A. E., Gill, H., Kunder, C., Stoyanova, T., Rusu, M., Loening, A. M., Ghanouni, et al
  2022
- **68Ga-PSMA-11 PET/MRI in patients with newly diagnosed intermediate or high-risk prostate adenocarcinoma: PET findings correlate with outcomes after definitive treatment.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Moradi, F., Duan, H., Song, H., Davidzon, G. A., Chung, B. I., Thong, A. E., Loening, A. M., Ghanouni, P., Sonn, G., Iagaru, A.
  2022

- **Positron emission tomography/computed tomography differentiates resectable thymoma from anterior mediastinal lymphoma.** *The Journal of thoracic and cardiovascular surgery*
  Byrd, C. T., Trope, W. L., Bhandari, P., Konsker, H. B., Moradi, F., Lui, N. S., Liou, D. Z., Backhus, L. M., Berry, M. F., Shrager, J. B.
  2022
- **Peptide Receptor Radionuclide Therapy (PRRT) in Advanced Pheochromocytoma and Paraganglioma From a Single Institution Experience**
  Duan, H., Ferri, V., Fisher, G. A., Shaheen, S., Davidzon, G. A., Moradi, F., Nguyen, J., Franc, B. L., Iagaru, A., Aparici, C.
  LIPPINCOTT WILLIAMS & WILKINS.2022: E42-E43
- **Clinical Applications of PET/MR Imaging.** *Radiologic clinics of North America*
  Moradi, F., Iagaru, A., McConathy, J.
  2021; 59 (5): 853-874
- **PROSPECTIVE EVALUATION OF F-18-DCFPYL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFPYL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES**
  Song, H., Nguyen, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2021: E1177-E1178
- **PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**
  Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2021: E1178
- **Prostate cancer: Molecular imaging and MRI.** *European journal of radiology*
  Moradi, F., Farolfi, A., Fanti, S., Iagaru, A.
  2021; 143: 109893
- **A Pilot Study of68Ga-PSMA11 PET/MRI and68GaRM2 PET/MRI for Biopsy Guidance in Patients with Suspected Prostate Cancer**
  Duan, H., Ferri, V., Ghanouni, P., Daniel, B., Hatami, N., Davidzon, G., Aparici, C., Moradi, F., Thong, A., Sonn, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2021
- **Perfusion Only Scans with and without SPECT/CT in the Era of COVID-19**
  Zhang, R., Moradi, F., Aparici, C., Davidzon, G., Nguyen, J., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2021
- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al
  2021
- **Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase 3, Multicenter Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
  Morris, M. J., Rowe, S. P., Gorin, M. A., Saperstein, L., Pouliot, F., Josephson, D. Y., Wong, J. Y., Pantel, A. R., Cho, S. Y., Gage, K. L., Piert, M. R., Iagaru, A., Pollard, et al
  2021
- **Prognostic value of bone marrow metabolism on pretreatment 18F-FDG PET/CT in patients with metastatic melanoma treated with anti-PD-1 therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Nakamoto, R., Zaba, L. C., Liang, T., Reddy, S. A., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A., Franc, B. L.
  2021
- **The Clinical Utility of 18F-Fluciclovine PET/CT in Biochemically Recurrent Prostate Cancer: an Academic Center Experience Post FDA Approval.** *Molecular imaging and biology*
  Nakamoto, R. n., Harrison, C. n., Song, H. n., Guja, K. E., Hatami, N. n., Nguyen, J. n., Moradi, F. n., Franc, B. L., Aparici, C. M., Davidzon, G. n., Iagaru, A. n.
  2021
- **Positron Emission Tomography and Molecular Imaging of Head and Neck Malignancies** *CURRENT RADIOLOGY REPORTS*
  Moradi, F.
  2020; 8 (11)

- **The Role of Positron Emission Tomography in Pancreatic Cancer and Gallbladder Cancer.** *Seminars in nuclear medicine*
  Moradi, F., Iagaru, A.
  2020; 50 (5): 434–46
- **Imaging Characteristics and Diagnostic Performance of 2-deoxy-2-[18F]fluoro-D-Glucose PET/CT for Melanoma Patients Who Demonstrate Hyperprogressive Disease When Treated with Immunotherapy.** *Molecular imaging and biology*
  Nakamoto, R., C Zaba, L., Rosenberg, J., Arani Reddy, S., W Nobashi, T., Ferri, V., Davidzon, G., Mari Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Lewis Franc, B.
  2020
- **Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast!** *AJR. American journal of roentgenology*
  Moradi, F., Iagaru, A.
  2020
- **A prospective study of Ga-68-RM2 PET/MRI in patients with biochemically recurrent prostate cancer and negative conventional imaging.**
  Baratto, L., Song, H., Duan, H., Aparici, C., Davidzon, G., Moradi, F., Srinivas, S., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2020
- **Prospective evaluation of F-18-DCFPyL PET/CT in biochemically recurrent prostate cancer: Analysis of lesion localization and distribution.**
  Song, H., Duan, H., Harrison, C., Guja, K., Hatami, N., Franc, B., Moradi, F., Aparici, C., Davidzon, G., Srinivas, S., Iagaru, A.
  AMER SOC CLINICAL ONCOLOGY.2020
- **Extrahepatic Ga-68-DOTATATE-Avid Tumor Volume and serum Chromogranin A Predict Short-Term Outcome of Lu-177-DOTATATE in Late-Stage Metastatic Gastroenteropancreatic Neuroendocrine Tumors**
  Song, H., Kunz, P., Franc, B., Moradi, F., Fisher, G., Aparici, C., Iagaru, A., Davidzon, G.
  SOC NUCLEAR MEDICINE INC.2020
- **Ga-68-PSMA-11 PET/MR Imaging before prostatectomy: correlation with surgical pathology and two-year follow up**
  Moradi, F., Baratto, L., Duan, H., Hatami, N., Davidzon, G., Sonn, G., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **PSMA-and GRPR-targeted PET: Preliminary Results in Patients with Biochemically Recurrent Prostate Cancer**
  Baratto, L., Duan, H., Hatami, N., Song, H., Davidzon, G., Franc, B., Aparici, C., Moradi, F., Nguyen, J., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy**
  Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2020
- **Imaging characteristics and diagnostic performance of F-18-FDG PET/CT for melanoma patients who demonstrate hyperprogressive disease when treated with immunotherapy**
  Nakamoto, R., Zaba, L., Rosenberg, J., Reddy, S., Nobashi, T., Davidzon, G., Aparici, C., Nguyen, J., Moradi, F., Iagaru, A., Franc, B.
  SOC NUCLEAR MEDICINE INC.2020
- **Toxicity identification and evaluation of peptide receptor radionuclide therapy (PRRT) for neuroendocrine tumors (NETs)**
  Duan, H., Girod, B., Ninatti, G., Ferri, V., Kunz, P., Fisher, G., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Aparici, C.
  SOC NUCLEAR MEDICINE INC.2020
- **INTERIM ANALYSIS RESULTS OF A PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**
  Baratto, L., Song, H., Duan, H., Aparici, C., Hatami, N., Davidzon, G., Moradi, F., Iagaru, A.
  LIPPINCOTT WILLIAMS & WILKINS.2020: E1118
- **Prevalence of Bone Metastases in Neuroendocrine Neoplasms by 68Ga DOTATATE PET Scan**
  Shaheen, S., Gardner, R., Sundaram, V., Hornbacker, K., Moradi, F., Wu, J., Kunz, P.
  LIPPINCOTT WILLIAMS & WILKINS.2020: 486
- **Fungal endocarditis resembling primary cardiac malignancy in a patient with B-cell ALL with culture confirmation.** *Radiology case reports*
  Girod, B. J., Guja, K. E., Davidzon, G., Chan, F., Zucker, E., Franc, B. L., Moradi, F., Iagaru, A., Aparici, C. M.
  2020; 15 (2): 117–19

- **Single institution experience with peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors (NET)**
  Duan, H., Ninatti, G., Girod, B., Ferri, V., Kunz, P. L., Fisher, G. A., Moradi, F., Davidzon, G., Franc, B., Iagaru, A., Mari, C.
  AMER SOC CLINICAL ONCOLOGY.2020
- **Quantification of brain oxygen extraction and metabolism with [15O]-gas PET: A technical review in the era of PET/MRI.** *NeuroImage*
  Fan, A. P., An, H. n., Moradi, F. n., Rosenberg, J. n., Ishii, Y. n., Nariai, T. n., Okazawa, H. n., Zaharchuk, G. n.
  2020: 117136
- **Patient Selection and Toxicities of PRRT for Metastatic Neuroendocrine Tumors and Research Opportunities.** *Current treatment options in oncology*
  Shaheen, S. n., Moradi, F. n., Gamino, G. n., Kunz, P. L.
  2020; 21 (4): 25
- **An unusual presentation of recurrent T cell lymphoma: angiocentric pattern of cutaneous uptake on [18F]FDG PET/CT.** *European journal of nuclear medicine and molecular imaging*
  Guja, K. E., Brown, R. n., Girod, B. n., Song, H. n., Harrison, C. n., Franc, B. L., Moradi, F. n., Davidzon, G. n., Iagaru, A. n., Aparici, C. M.
  2020
- **Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy.** *European journal of nuclear medicine and molecular imaging*
  Nakamoto, R. n., Zaba, L. C., Rosenberg, J. n., Reddy, S. A., Nobashi, T. W., Davidzon, G. n., Aparici, C. M., Nguyen, J. n., Moradi, F. n., Iagaru, A. n., Franc, B. L.
  2020
- **Prospective Evaluation in an Academic Center of 18F-DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., Moradi, F., Mari Aparici, C., Davidzon, G., Iagaru, A.
  2019
- **Prospective Evaluation of F-18-DCFPyL PET/CT and Conventional Imaging in Patients with Biochemically Recurrent Prostate Cancer**
  Song, H., Harrison, C., Guja, K., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019
- **Prospective evaluation of F-18- DCFPyL in Patients with Biochemically Recurrent Prostate Cancer: Positivity Rate and Correlation with PSA levels**
  Harrison, C., Song, H., Franc, B. L., Guja, K., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019
- **Prospective Comparison of F-18-DCFPyL PET/CT with F-18-NaF PET/CT for Detection of Skeletal Metastases in Biochemically Recurrent Prostate Cancer**
  Duan, H., Song, H., Baratto, L., Khalaf, M., Hatami, N., Franc, B., Moradi, F., Davidzon, G., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019
- **Quantification of uptake in Ga-68-DOTATATE PET: Correlation between standardized uptake values and patient factors**
  Moradi, F., Guja, K., Aparici, C., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2019
- **Perfusion Scintigraphy in Diagnosis and Management of Thromboembolic Pulmonary Hypertension.** *Radiographics : a review publication of the Radiological Society of North America, Inc*
  Moradi, F., Morris, T. A., Hoh, C. K.
  2019; 39 (1): 169-185
- **Glucose-corrected standardized uptake value (SUVgluc) is the most accurate SUV parameter for evaluation of pulmonary nodules** *AMERICAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING*
  Jahromi, A., Moradi, F., Hoh, C. K.
  2019; 9 (5): 243–47
- **Comparison of three interpretation criteria of 68Ga-PSMA11 PET based on inter- and intra-reader agreement.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*
  Toriihara, A. n., Nobashi, T. n., Baratto, L. n., Duan, H. n., Moradi, F. n., Park, S. n., Hatami, N. n., Aparici, C. n., Davidzon, G. n., Iagaru, A. n.
  2019

- **Spectrum of Ga-68-DOTA TATE Uptake in Patients With Neuroendocrine Tumors** *CLINICAL NUCLEAR MEDICINE*
  Moradi, F., Jamali, M., Barkhodari, A., Schneider, B., Chin, F., Quon, A., Mittra, E. S., Iagaru, A.
  2016; 41 (6): E281-E287
- **Physiological distribution of Ga-68-DOTA-TATE: an atlas of standardized uptake values**
  Moradi, F., Minamimoto, R., Jamali, M., Barkhodari, A., Quon, A., Mittra, E., Gambhir, S., Iagaru, A.
  SOC NUCLEAR MEDICINE INC.2015